Metformin for the Prevention of CRA Recurrence

• Status: Recruiting
• Trial end date: 2022-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Most of the sporadic colorectal cancer (CRC )develop from colorectal adenoma (CRA), patients with CRA have a high risk of recurrence and development of metachronous CRA or CRC after removal, therefore, the investigators conducted this clinical trial to explore the chemoprevetion effect of metformin for CRA recurrence after removal.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jing-yuan Fang, MD, Ph. D
• Treatments: Metformin

Criteria

Inclusion Criteria:

1. Aged 40-80 years without diabetes;

2. CRAs removed without recurrence before recruitment;

3. Must sign the consent form after being fully informed and understanding the purpose and procedure of this study.

Exclusion Criteria:

1. Familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome);

2. Regularly taking aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclo-oxygenase 2 (COX2) inhibitors, calcium or vitamin D;

3. Have a history of gastrointestinal surgery;

4. Have severe heart, liver or kidney disease ;

5. Have cancer history;

6. Women with pregnant, during breast-feeding period, or with expect pregnancy;

7. Diabetes（taking diabetes medicines or HbA1c>6.5%);

8. Inflammatory bowel disease;

9. Mental illness;

10. Intolerant to metformin;

11. Cannot tolerate colonoscopy;

12. Staffs in this clinical trial;

13. Poor bowel preparation for colonoscopy or the examination time is shorter than 6 minutes;

14. Unsuitable for inclusion by the investigator